• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Inhibrx Biosciences, Inc. - Common Stock (NQ:INBX)

    78.51 +1.46 (+1.89%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Inhibrx Biosciences, Inc. - Common Stock

    < Previous 1 2 3 Next >
    Unusual volume stocks in Thursday's session
    Discover the stocks with unexpected trading volume in today's session on the US markets. 
    Via Chartmill
    The trading volume of these stocks is deviating from the norm in today's session.
    Unusual volume stocks are being observed in Tuesday's session. 
    Via Chartmill
    US Stocks Jump To Records Amid Weak Inflation: Investor Fear Eases, Greed Index Remains In 'Fear' Zone
    Stocks hit all-time highs as inflation eased, boosting confidence for Fed rate cut. Fear & Greed Index shows fear, but higher stock prices. 
    Via Benzinga
    Topics Economy
    Inhibrx Biosciences Soars Over 90% on Breakthrough Rare Bone Cancer Trial Results
    San Diego, CA – October 24, 2025 – Inhibrx Biosciences, Inc. (NASDAQ: INBX) witnessed an extraordinary surge in its stock price today, rocketing by over 94% in early trading, following the announcement... 
    Via MarketMinute
    Why Is INBX Stock Rising Today?
    Via Stocktwits
    INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024
    INBX stock results show that Inhibrx beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Here are the top movers in Friday's session.
    Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session. 
    Via Chartmill
    Stocks Soar To Records After Weak Inflation, Ford Jumps 10%: What's Moving Markets Friday?
    Wall Street surged to fresh all-time highs Friday as a softer-than-expected inflation reading strengthened market conviction that the Federal Reserve will cut interest rates by 25 basis points at its... 
    Via Benzinga
    Topics Economy
    12 Health Care Stocks Moving In Friday's Intraday Session
     
    Via Benzinga
    What's going on in today's session
    Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
    Via Chartmill
    Dow Jumps Over 500 Points; US Consumer Sentiment Declines In October
     
    Via Benzinga
    Topics Stocks
    Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment
    San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly... 
    Via MarketMinute
    Ford, Inhibrx Biosciences, Comfort Systems, Western Union And Other Big Stocks Moving Higher On Friday
     
    Via Benzinga
    Which stocks are gapping on Friday?
    Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
    Via Chartmill
    Get insights into the top gainers and losers of Friday's pre-market session.
    The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
    Via Chartmill
    12 Health Care Stocks Moving In Friday's Pre-Market Session
     
    Via Benzinga
    Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    Why Are Inhibrx Biosciences Shares Soaring 76% After Hours?
    Inhibrx Biosciences shares surged nearly 76% in after-hours trading Thursday after the company reported positive Phase 2 trial results for its cancer drug Ozekibart. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
     
    Via Benzinga
    Get insights into the top gainers and losers of Thursday's after-hours session.
    After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
    Via Chartmill
    12 Health Care Stocks Moving In Wednesday's After-Market Session
     
    Via Benzinga
    Inhibrx Biosciences Beats Earnings
    Via The Motley Fool
    Topics Intellectual Property
    Around $2M Bet On Franklin Resources? Check Out These 4 Stocks Executives Are Buying
     
    Via Benzinga
    Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying
     
    Via Benzinga
    INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024
    INBX stock results show that Inhibrx Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Top 4 Health Care Stocks That Are Preparing To Pump This Month
     
    Via Benzinga
    The NVDA Earnings Effect And What It Means For The Current Market Momentum
    Discover the confluence zone that will make or break the S&P 500 and the preliminary supply (early distribution) you need to be aware of. 
    Via Talk Markets
    Topics Stocks
    Is The Stock Market Ready To Plunge? The Warning Signs Are Here...
    Find out how to spot the exhaustion of demand and the bearish analogue you could refer to to anticipate the down move. 
    Via Talk Markets
    Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx
    The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency. 
    Via Investor's Business Daily
    French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B
    Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected... 
    Via Benzinga
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.